Project: Targeting hepatitis B virus with CRISPR-Cas9 as a novel therapeutic approach
Littlejohn Group
There is no cure for chronic hepatitis B infection, due in part to the presence of a reservoir of hepatitis B virus (HBV) DNA that is not targeted by any current therapy. Our laboratory is developing CRISPR-Cas9 to target the HBV DNA reservoir as a novel therapeutic approach. In this project we will compare multiple CRISPR-Cas9 approaches using in vitro models to evaluate their effectiveness and suitability for use as a new therapy. Students will learn multiple laboratory techniques including cell culture, transfection and infection, examination of DNA and protein expression by qPCR, quantitative serology, PCR, sequencing and western blotting. This project will make important advances towards HBV cure, benefiting the nearly 300 million people worldwide who live with chronic HBV infection.
Contact project supervisor for further
information and application enquiries
Littlejohn Group
1 vacancies
The Littlejohn group focuses on using Crispr-Cas to develop novel therapeutic approaches towards curing chronic HBV infection. This is done using a range of cell culture and in vivo models to measure the impact on HBV replication and protein expression.
Littlejohn Group Current Projects
-
Targeting hepatitis B virus with CRISPR-Cas9 as a novel therapeutic approach
Master of Biomedical Science, Honours
Research degrees at the Doherty Institute are administered by the University of Melbourne.